Skip to contentL
Lipella Pharmaceuticals Inc.
L
LIPOLipella Pharmaceuticals Inc. Q1 2025 · 10-Q
Revenue$129.39K$129.39K−11.3% vs Q1 2024 Net Income-$1.31M-$1.31MN/M vs Q1 2024 EPS Diluted-$0.64-$0.64N/M vs Q1 2024 Operating Income-$1,327,821N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipella Pharmaceuticals Inc. · CIK 1347242 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1026.2%−191.5 pt vs Q1 2024
Net margin-1009.8%−192.8 pt vs Q1 2024
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end